GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » E10

Evofem Biosciences (Evofem Biosciences) E10 : $-23,395.30 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Evofem Biosciences's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.160. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-23,395.30 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-28), Evofem Biosciences's current stock price is $0.0159. Evofem Biosciences's E10 for the quarter that ended in Mar. 2024 was $-23,395.30. Evofem Biosciences's Shiller PE Ratio of today is .


Evofem Biosciences E10 Historical Data

The historical data trend for Evofem Biosciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences E10 Chart

Evofem Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -23,153.30

Evofem Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24,303.80 -23,938.00 -23,544.60 -23,153.30 -23,395.30

Competitive Comparison of Evofem Biosciences's E10

For the Biotechnology subindustry, Evofem Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evofem Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Shiller PE Ratio falls into.



Evofem Biosciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evofem Biosciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.16/131.7762*131.7762
=-0.160

Current CPI (Mar. 2024) = 131.7762.

Evofem Biosciences Quarterly Data

per share eps CPI Adj_EPS
201406 -1,933.390 100.560 -2,533.573
201409 -3,427.360 100.428 -4,497.206
201412 -2,384.090 99.070 -3,171.165
201503 -5,624.960 99.621 -7,440.551
201506 -7,762.450 100.684 -10,159.580
201509 -14,174.900 100.392 -18,606.301
201512 -7,762.450 99.792 -10,250.341
201603 -4,949.970 100.470 -6,492.342
201606 -2,137.490 101.688 -2,769.944
201609 -1,912.490 101.861 -2,474.162
201612 -1,574.990 101.863 -2,037.509
201703 -5,887.470 102.862 -7,542.406
201706 -7,087.460 103.349 -9,036.930
201709 -71,830.900 104.136 -90,896.898
201712 -19,781.200 104.011 -25,061.665
201803 -8,662.460 105.290 -10,841.594
201806 -2,081.240 106.317 -2,579.629
201809 -1,331.240 106.507 -1,647.087
201812 -1,087.490 105.998 -1,351.964
201903 -1,256.240 107.251 -1,543.513
201906 -1,818.740 108.070 -2,217.708
201909 -562.497 108.329 -684.244
201912 -506.247 108.420 -615.304
202003 -749.996 108.902 -907.532
202006 -1,706.240 108.767 -2,067.182
202009 -693.747 109.815 -832.486
202012 -937.495 109.897 -1,124.141
202103 -1,058.020 111.754 -1,247.574
202106 -501.250 114.631 -576.219
202109 -900.000 115.734 -1,024.749
202112 -618.747 117.630 -693.161
202203 -360.250 121.301 -391.360
202206 -580.480 125.017 -611.865
202209 -4.390 125.227 -4.620
202212 -11.656 125.222 -12.266
202303 -1.850 127.348 -1.914
202306 -5.430 128.729 -5.559
202309 0.100 129.860 0.101
202312 -0.558 129.419 -0.568
202403 -0.160 131.776 -0.160

Add all the adjusted EPS together and divide 10 will get our e10.


Evofem Biosciences  (OTCPK:EVFM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Evofem Biosciences E10 Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Evofem Biosciences (Evofem Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Executives
Yan Zhang officer: Chief Financial Officer 6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar director, 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip director 12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca officer: Chief Commercial Officer 12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier director, officer: Chief Executive Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick officer: General Counsel and Secretary 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File officer: Chief Financial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans officer: Chief Commercial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd. 10 percent owner 1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd 10 percent owner 65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp 10 percent owner 767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell officer: Chief Medical Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130